Streetbeat News

AVBP

ArriVent BioPharma Inc.

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

35.87

Mkt cap

1.1B

Volume

193K

High

36.00

P/E Ratio

-15.00

52-wk high

36.20

Low

33.16

Div yield

N/A

52-wk low

14.35

HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on ArriVent BioPharma (NASDAQ:AVBP) and maintained a $25 price target.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 10:13 am

ArriBent BioPharma has entered into a collaboration with Jiangsu Alphamab Biopharmaceuticals, a subsidiary of Alphamab Oncology, to develop cancer-focused antibody-drug conjugates. The deal includes upfront and potential milestone payments to Alphamab of up to $615.5 million.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:09 am

HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on ArriVent BioPharma (NASDAQ:AVBP) and maintained a $25 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:14 am

ArriVent BioPharma (NASDAQ:AVBP) reported Q1 earnings with losses of $(0.70) per share, surpassing the analyst consensus estimate of $(1.05) by 33.33%. This indicates a better-than-expected financial performance for the quarter.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 12:15 pm

HC Wainwright & Co. analyst Robert Burns initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and a price target of $25.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 10:12 am

ProfoundBio Inc. is set to be acquired by Genmab A/S (NASDAQ:GMAB) for $1.8 billion, marking the fourth acquisition of a China-related innovative drugmaker by a foreign company in recent months. This trend reflects the challenges Chinese drugmakers face in becoming profitable due to high development costs and market pressures. ProfoundBio, with its advanced cancer treatment drugs, represents a valuable addition to Genmab's portfolio. Other notable acquisitions include Gracell Biotechnologies by AstraZeneca, SanReno Therapeutics by Novartis, and AnHeart Therapeutics by Nuvation Bio Inc. (NASDAQ:NUVB). Eli Lilly (NYSE:LLY) is also mentioned as a backer of ProfoundBio.

Portfolio Pulse from The Bamboo Works

April 08, 2024 | 3:43 pm

ArriVent BioPharma reported a FY23 EPS of $(32.38), compared to $(28.90) in FY22. R&D expenses increased to $64.9M, mainly due to furmonertinib trials. G&A expenses rose to $9.7M, attributed to costs of operating as a public company and higher personnel costs. The net loss widened to $69.3M from $37.0M. However, with $150.4M in cash and upcoming IPO proceeds, the company expects to fund operations into 2026.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:38 pm

Jefferies analyst Kelly Shi initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 4:37 pm

Citigroup analyst Yigal Nochomovitz initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 11:51 am

Goldman Sachs analyst Corinne Johnson initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and a price target of $27.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 10:47 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.